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Introduction 
Accumulating evidence indicates that metabolic dysfunction with visceral obesity is a major 
medical problem associated with the development of hypertension, type 2 diabetes (T2DM) and 
dyslipidemia, and ultimately severe cardiovascular disease. Since obesity with visceral fat is related 
to a variety of metabolic disorders and has a serious impact on the cost of health care, the treatment 
of obesity has become a critical issue. Although the standard treatment for obesity is a combination 
of diet and exercise therapy, it is often extremely difficult for obese people to reduce their body 
weight in this way compared with healthy people, in part because of their excessive appetite. 
Therefore, to prevent the development of obesity, various anti-obesity drugs and bariatric surgery 
have been developed as adjunct therapies of obesity in western medicine. However, anti-obesity 
drugs and bariatric surgery have only been able to help a limited number of severely obese people 
because of side effects and invasiveness of the procedure (Dietrich MO and Horvath TL, 2012).  
Bofu-tsusho-san (BOF) is one of oriental herbal medicine and is clinically available to treat obesity 
in Japan. In previous studies, BOF has been reported to exert its anti-obesity effect in obese patients 
as well as various obesity-model animals (Hioki C et al., 2004; Yoshida T et al., 1995). However, the 
mechanism of its beneficial effect is not fully elucidated. Here, we investigated mechanism of 
therapeutic effects of BOF on KKAy mice, a model of human metabolic disorders with visceral 
obesity. 
 
Methods 
Male KKAy mice (9 weeks old) were divided into two groups and fed a standard powdered diet 
(CE-2, the control group) or a powdered diet containing BOF (CE-2 containing 4.7% BOF, the BOF 
group) for 8 weeks. During the experiment, body weight, food intake and systolic blood pressure 
(SBP) by tail-cuff method were measured. The tissues were collected under anesthesia at the end of 
the experimental period.  
To examine the acute effects of BOF on food intake and an orexigenic hormone, KKAy mice (13 - 
14 weeks of age) fed a standard diet were fasted for 24 hours and were then administered BOF (5000 
mg/kg) dissolved in 1mL of distilled water per 100 g of body weight via a stomach tube, and then 
24-hour food intake and plasma acylated-ghrelin level were measured.  
 
Results 
Chronic BOF administration persistently decreased food intake, body weight gain, LDL-C and SBP 
(Control vs BOF; SBP, 122 ± 4 vs 113 ± 2 mmHg, P < 0.05). In addition, both tissue weight and cell 
size of visceral white adipose tissue (WAT) were decreased, with concomitant increases in the 
expression of adiponectin and peroxisome proliferator-activated receptors (PPARs) genes in visceral 
WAT as well as the circulating adiponectin level by BOF treatment (Control vs BOF; plasma 
adiponectin level, 6.1 ± 0.2 vs 7.9 ± 0.3 μg/ml, P < 0.001). Furthermore, gene expression of 
uncoupling protein-1, a thermogenesis index by mitochondria, in brown adipose tissue (BAT) and 
rectal temperature were both elevated by BOF. Intriguingly, plasma acylated-ghrelin, an active form 
of orexigenic hormone, and short-term food intake were significantly decreased by single bolus 
administration of BOF (Control vs BOF; plasma acylated-ghrelin level, 25.1 ± 1.1 vs 20.5 ± 1.7 
fmol/ml, P < 0.05). 
 
Discussion 
 In the present study, we showed that 1) BOF persistently decreased food intake and body weight 
gain; 2) BOF consistently decreased blood pressure without affecting heart rate; 3) BOF decreased 
WAT weight and adipocyte hypertrophy, and ameliorated the adipocytokine dysregulation in WAT; 
4) BOF increased UCP-1 mRNA expression in BAT and also the rectal temperature and 5) BOF 
decreased the short-term food intake and the plasma acylated-ghrelin level in KKAy mice, a model 
of human metabolic disorders with visceral obesity, T2DM, dyslipidemia and hypertension. 
 PPARs are critical regulators of adipocyte differentiation and are reported to activate adiponectin 
gene expression in WAT (Hiuge A et al., 2007; Maeda N et al., 2001). Furthermore, adiponectin is 
reported to play a protective role against hypertension (Ohashi K et al., 2006; Wang ZV and Scherer 
PE, 2008). UCP-1 is specifically expressed in BAT and uncouples mitochondrial oxidative 
phosphorylation by bypassing the electrochemical gradient across the inner membrane from the 
F1-ATPase and thereby consumes energy as heat (Yoshida T et al., 1995). Thus, the elevated rectal 
temperature, induced by activating BAT thermogenesis may contribute to the efficient suppression of 
adipocyte hypertrophy in WAT. Ghrelin, an orexigenic hormone secreted mainly from the stomach, 
plays an important role in the regulation of food intake (Kojima M et al., 1999). Ghrelin is reported 
to cause a significant increase in food intake by exerting a potent appetite-stimulating effect by 
altering orexigenic neuropeptides in the hypothalamus (Kamegai J et al., 2000; Seoane LM et al., 
2003; van der Lely AJ et al., 2004). Thus, we hypothesized that BOF exerts a potent 
appetite-inhibitory effect possibly via suppression of the ghrelin system. We demonstrated that the 
acute BOF administration significantly decreased the 24-hour food intake with a concomitant 
reduction of circulating concentration of activated ghrelin. This is the first report showing that BOF 
exerts an appetite-inhibitory effect via its suppression on the ghrelin system. 
Collectively, from the results of present study, we present a schema that would explain the 
mechanisms of the combinatorial favorable metabolic modulation including antihypertensive effect 
mediated by BOF (Figure 1). BOF acts on adipose tissue to decrease adipocyte hypertrophy in WAT 
by activation of BAT thermogenesis and amelioration of adipocytokine dysregulation. BOF probably 
acts on the ghrelin system to exert an appetite inhibitory effect. The improvement in adipose tissue 
function by amelioration of adipocytokine dysregulation and the reduction of food intake by appetite 
inhibition may contribute to the blood pressure lowering effect as well as favorable metabolic 
modulation by BOF in KKAy mice. A limitation of the present study is that other factors such as a 
diuretic effect and/or an inhibitory effect on sympathetic nerve activity, in addition to a decrease in 
food intake via appetite suppression, may be involved in the BOF-mediated blood pressure lowering, 
and these issues should be also addressed by further studies. 
In conclusion, these results indicate that BOF exerts a combinatorial favorable metabolic 
modulation including antihypertensive effect, at least partially, via its beneficial effect on adipose 
tissue function and its appetite-inhibitory property through suppression on the ghrelin system. 
 
 
 
Figure 1. Schema of the mechanisms of beneficial effects induced by BOF.  
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